Table 1.
Characteristics of cases and controls
| Cases (n = 6,763), % | Controls (n = 26,341), % | Crude OR [95% CI] | |
|---|---|---|---|
| Gender | |||
| Male | 1,834 (27.1) | 7,203 (27.3) | |
| Female | 4,929 (72.9) | 19,138 (72.7) | |
| Age (years) | |||
| 18–49 | 452 (6.7) | 1,808 (6.9) | |
| 50–69 | 1,061 (15.7) | 4,239 (16.1) | |
| ≥70 | 5,250 (77.6) | 20,294 (77.0) | |
| Hospitalisation before the index date | |||
| Cardiovascular disease | 359 (5.3) | 1,289 (4.9) | 1.10 [0.98–1.25] |
| Cerebrovascular disease | 296 (4.4) | 565 (2.1) | 2.12 [1.84–2.45] |
| Parkinson’s disease | 23 (0.3) | 41 (0.2) | 2.24 [1.34–3.75] |
| Mental disorders | 24 (0.4) | 36 (0.1) | 2.54 [1.51–4.27] |
| Drug use 6 months before the index date | |||
| Benzodiazepinesa | 967 (14.3) | 2,751 (10.4) | 1.44 [1.33–1.56] |
| Antidepressants | 643 (9.5) | 1,343 (5.1) | 2.00 [1.81–2.21] |
| Antipsychotics | 412 (6.2) | 921 (3.5) | 1.79 [1.58–2.02] |
| Current drug use at index date | |||
| Amantadine | 30 (0.4) | 42 (0.2) | 2.78 [1.74–4.44] |
| Selegeline | 56 (0.8) | 51 (0.2) | 4.37 [2.98–6.41] |
| Anticholinergics | 43 (0.6) | 67 (0.3) | 2.52 [1.72–3.70] |
| Cathechol-O-methyltransferase inhibitors | 1 (0.0) | 5 (0.0) | 0.80 [0.09–6.85] |
a3 months before the index date